Clene Inc. Cash Flow Conversion Efficiency
Clene Inc. cash flow conversion efficiency. Based on the latest financial reports, Clene Inc. (CLNN) has a cash flow conversion efficiency ratio of 0.104x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.59 Million) by net assets ($-24.78 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Clene Inc. (2018–2025)
Cash flow conversion efficiency of Clene Inc. from 2018 to 2025. This chart illustrates how Clene Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View CLNN share price today for real-time trading data and today's change.
Clene Inc. Cash Flow Conversion Ratio Explained
Clene Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Clene Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Clene Inc. ranked by their cash flow conversion efficiency. Also see Clene Inc. (CLNN) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Francotyp-Postalia Holding AG
F:FPH
|
0.005x |
|
Atende S.A.
WAR:ATD
|
0.055x |
|
AGX Group Berhad
KLSE:0299
|
0.039x |
|
Changhae Ethanol Co. Ltd
KQ:004650
|
0.102x |
|
Sequana Medical NV
BR:SEQUA
|
0.254x |
|
Helium Evolution Inc
V:HEVI
|
-0.028x |
|
Sinil Pharmaceutical Co. Ltd
KQ:012790
|
0.017x |
|
RSUPPORT Co. Ltd
KQ:131370
|
0.000x |
Annual Cash Flow Conversion Efficiency for Clene Inc. (2018–2025)
The table below shows the annual cash flow conversion efficiency of Clene Inc. from 2018 to 2025. Review Clene Inc. financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-17.59 Million | $-18.55 Million | 1.054x | -56.22% |
| 2024-12-31 | $-8.86 Million | $-21.33 Million | 2.408x | +206.86% |
| 2023-12-31 | $13.39 Million | $-30.17 Million | -2.253x | +81.30% |
| 2022-12-31 | $3.24 Million | $-39.01 Million | -12.052x | -338.46% |
| 2021-12-31 | $12.60 Million | $-34.62 Million | -2.749x | +95.05% |
| 2020-12-31 | $341.00K | $-18.93 Million | -55.510x | -1955.61% |
| 2019-12-31 | $4.89 Million | $-13.20 Million | -2.700x | -6474.48% |
| 2018-12-31 | $5.00 Million | $-205.37K | -0.041x | -- |
About Clene Inc.
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral … Read more